The Effect of Intravenous Tranexamic Acid in Percutaneous Renal Biopsy: A Single Center, Triple-blinded, Randomized Controlled Trial

The Effect of Intravenous Tranexamic Acid in Percutaneous Renal Biopsy: A Single Center, Triple-blinded, Randomized Controlled Trial - TRANExamic acid in renal bioPSY study (TRANEPSY study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019830

Enrollment

Registered

2015-11-25

Start date

2015-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pathological states in which percutaneous renal biopsy is indicated

Interventions

High dose group (1,000mg): intravenous bolus injection of 500mg of tranexamic acid just before the biopsy, and drip infusion of 500mg of tranexamic acid with saline solution after the biopsy Low dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 20 years or more who will undergo a percutaneous biopsy of their native kidney

Exclusion criteria

Exclusion criteria: - Those for whom amyloidosis is suspected - Those for whom tranexamic acid is contraindicated - Pregnant or breast-feeding women - Those who need tranexamic acid for treatment - Those who are judged to be unsuitable as research subjects by the investigators

Design outcomes

Primary

Measure	Time frame
Perirenal hematoma, measured by ultrasonography on the morning following the percutaneous renal biopsy	—

Countries

Japan

Contacts

Public ContactJunichi Izawa

Kyoto University Department of Preventive Services, Kyoto University Graduate School of Public Health

jizawa13@gmail.com075-753-2426

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026